289 related articles for article (PubMed ID: 16322991)
81. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
82. [Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function].
Kono M; Sakata Y; Sugawara T; Abe K; Miyamori S; Miura S; Hata Y; Funaki M; Inata J; Kanehara M; Hiraki K; Iwamoto Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2587-90. PubMed ID: 25596053
[TBL] [Abstract][Full Text] [Related]
83. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
[TBL] [Abstract][Full Text] [Related]
84. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
[TBL] [Abstract][Full Text] [Related]
85. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
Léger F; Loos WJ; Fourcade J; Bugat R; Goffinet M; Mathijssen RH; Verweij J; Sparreboom A; Chatelut E
Br J Cancer; 2004 Jan; 90(2):343-7. PubMed ID: 14735174
[TBL] [Abstract][Full Text] [Related]
86. [Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma].
Fernández Megía MJ; Alós Almiñana M; Esquer Borrás J
Farm Hosp; 2004; 28(6):433-9. PubMed ID: 15628946
[TBL] [Abstract][Full Text] [Related]
87. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
88. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
[TBL] [Abstract][Full Text] [Related]
89. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
90. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
91. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
[TBL] [Abstract][Full Text] [Related]
92. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.
Warwick AB; Malempati S; Krailo M; Melemed A; Gorlick R; Ames MM; Safgren SL; Adamson PC; Blaney SM
Pediatr Blood Cancer; 2013 Feb; 60(2):237-41. PubMed ID: 22745043
[TBL] [Abstract][Full Text] [Related]
93. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
94. Population pharmacokinetics of the novel anticancer agent KRN7000.
Crul M; Mathôt RA; Giaccone G; Punt CA; Rosing H; Hillebrand MX; Ando Y; Nishi N; Tanaka H; Schellens JM; Beijnen JH
Cancer Chemother Pharmacol; 2002 Apr; 49(4):287-93. PubMed ID: 11914907
[TBL] [Abstract][Full Text] [Related]
95. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.
Knebel W; Davis JC; Sanders WD; Fessler B; Yarboro C; Pucino F; Boumpas DT
Pharmacotherapy; 1998; 18(6):1224-9. PubMed ID: 9855320
[TBL] [Abstract][Full Text] [Related]
96. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.
Kumthekar P; Grimm SA; Avram MJ; Kaklamani V; Helenowski I; Rademaker A; Cianfrocca M; Gradishar W; Patel J; Mulcahy M; McCarthy K; Raizer JJ
J Neurooncol; 2013 Apr; 112(2):247-55. PubMed ID: 23354655
[TBL] [Abstract][Full Text] [Related]
97. [Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy].
Sakata Y; Iwamoto Y; Inata J; Matsumoto S; Miyamori S; Nakashima K; Sakamoto S; Kanehara M; Kitaguchi S; Hiraki K
Gan To Kagaku Ryoho; 2012 Jun; 39(6):927-32. PubMed ID: 22705687
[TBL] [Abstract][Full Text] [Related]
98. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients.
Srinivasan M; Chaturvedula A; Fossler MJ; Patil A; Gota V; Prabhash K
J Clin Pharmacol; 2019 Sep; 59(9):1216-1224. PubMed ID: 30973978
[TBL] [Abstract][Full Text] [Related]
99. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
Bos AM; Boom K; Vinks AA; Boezen HM; Wanders J; Dombernovsky P; Aamdal S; de Vries EG; Uges DR
Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
[TBL] [Abstract][Full Text] [Related]
100. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.
Sabot C; Debord J; Roullet B; Marquet P; Merle L; Lachatre G
Int J Clin Pharmacol Ther; 1995 Mar; 33(3):164-9. PubMed ID: 7599915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
